Diamidines as antitrypanosomal, antileishmanial and antimalarial agents

Current Opinion in Investigational Drugs

Volumn 7, Issue 2, 2006, Pages 147-157

  Werbovetz, Karl ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Diamidine; Leishmania; Pentamidine; Plasmodium; Trypanosomes

Indexed keywords

5,6,7,8 TETRAHYDROIMIDAZO[1,2 A]PYRIDINE; ADENINE; ADENOSINE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; AMIDOXIME; ANTILEISHMANIAL AGENT; ANTIMALARIAL AGENT; ANTITRYPANOSOMAL AGENT; BUTENEAMIDINE; CARBAZOLE DERIVATIVE; CARRIER PROTEIN; CHOLINE; DB 289; DIAMIDINE DERIVATIVE; DIBENZOFURAN DERIVATIVE; DIBENZOTHIOPHENE DERIVATIVE; DIMINAZENE ACETURATE; DNA; DNA TOPOISOMERASE; FURAMIDINE; HEMATIN; HEMOZOIN; OLIGOMYCIN; PENTAMIDINE; PLASMEPSIN I; PROPAMIDINE; RO 40 4388; STILBAMIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACANTHAMOEBA KERATITIS; AFRICAN TRYPANOSOMIASIS; ANTIMALARIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; CARDIOTOXICITY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; HUMAN; HYPOTENSION; IN VIVO STUDY; INJECTION SITE PAIN; LEISHMANIA; MALARIA; NEPHROTOXICITY; NONHUMAN; PLASMODIUM; REVIEW; TRYPANOSOMA;

ANIMALS; ANTIMALARIALS; ANTIPROTOZOAL AGENTS; BENZAMIDINES; CHAGAS DISEASE; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; LEISHMANIA; LEISHMANIASIS; MALARIA, FALCIPARUM; PENTAMIDINE; PLASMODIUM FALCIPARUM; PRODRUGS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS, AFRICAN;

EID: 32544437658     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Fairlamb A: Chemotherapy of human African trypanosomiasis: Current and future prospects. Trends Parasitol (2003) 19(11):488-494.
2. Chagas: World Health Organization, Geneva, Switzerland (2004). http://www.who.int/ctd/chagas/burdens.htm
3. Leishmaniasis: Background information: World Health Organization, Geneva, Switzerland (2005). http://www.who.int/leishmaniasis/en/
4. What is Malaria?: World Health Organization, Geneva, Switzerland (2005). http://mosquito.who.int/cmc_upload/0/000/015/372/RBMInfosheet_1.htm
5. Croft SL, Barrett MP, Urbina JA: Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol (2005) 21(11):508-512.
6. Ouellette M, Drummelsmith J, Papadopoulou B: Leishmaniasis: Drugs in the clinic, resistance and new developments. Drug Resistance Updates (2004) 7(4-5):257-266.
7. Kremsner P, Krishna S: Antimalarial combinations. Lancet (2004) 364(9430):285-294.
8. Arav-Boger R, Shapiro T: Molecular mechanisms of resistance in antimalarial chemotherapy: The unmet challenge. Annu Rev Pharmacol Toxicol (2005) 45:565-585.
9. Eisler MC, Brandt J, Bauer B, Clausen PH, Delespaux V, Holmes PH, Ilemobade A, Machila N, Mbwambo H, McDermott J, Mehlitz D et al: Standardised tests in mice and cattle for the detection of drug resistance in tsetse-transmitted trypanosomes of African domestic cattle. Vet Parasitol (2001) 97(3):171-182.
10. Seal D: Treatment of Acanthamoeba keratitis. Expert Rev Anti-Infective Ther (2003) 1(2):205-208.
11. Kovacs JA, Gill VJ, Meshnick S, Masur H: New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. J Am Med Assoc (2001) 286(19):2450-2460.
12. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S: Treatment options for visceral leishmaniasis: A systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis (2005) 5(12):763-774.
13. Feddersen A, Sack K: Experimental studies on the nephrotoxicity of pentamidine in rats. J Antimicrob Chemother (1991) 28(3):437-446.
14. Antoniou T, Gough KA: Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: Case report and review of the literature. Phamacotherapy (2005) 25(6):899-903.
15. Salamone FR, Cunha BA: Update on pentamidine for the treatment of Pneumocystis carinii pneumonia. Clin Pharm (1988) 7(7):501-510.
16. Assan R, Perronne C, Assan D, Chotard L, Mayaud C, Matheron S, Zucman D: Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care (1995) 18(1):47-55.
17. Singh S, Sivakumar R: Challenges and new discoveries in the treatment of leishmaniasis. J Infect Chemother (2004) 10(6):307-315.
18. Wilson WD, Nguyen B, Tanious FA, Mathis A, Hall JE, Stephens CE, Boykin DW: Dications that target the DNA minor groove: Compound design and preparation, DNA interactions, cellular distribution and biological activity. Curr Med Chem-Anti-Cancer Agents (2005) 5(4):389-408.
19. Bitonti A, Dumont J, McCann P: Characterization of Trypanosoma brucei brucei S-adenosyl-L-methionine decarboxylase and its inhibition by Berenil, pentamidine, and methylglyoxal bis(guanylhydrazone). Biochem J (1986) 237(3):685-689.
20. Morty RE, Troeberg L, Pike RN, Jones R, Nickel P, Lonsdale-Eccles JD, Coetzer TH: A trypanosome oligopeptidase as a target for the trypanocidal agents pentamidine, diminazine and suramin. FEBS Lett (1998) 433(3):251-256.
21. Shapiro TA, Englund PT: Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs. Proc Natl Acad Sci USA (1990) 87(3):950-954.
22. Carter NS, Berger BJ, Fairlamb AH: Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J Biol Chem (1995) 270(47):28153-28157.
23. Carter NS, Fairlamb AH: Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature (1993) 361(6408):173-176.
24. de Koning HP: Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: Implications for cross-resistance with arsenicals. Mol Pharmacol (2001) 59(3):586-592.
25. Matovu E, Stewart ML, Geiser F, Brun R, Maser P, Wallace LJ, Burchmore RJ, Enyaru JC, Barrett MP, Kaminsky R, Seebeck T et al: Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryotic Cell (2003) 2(5):1003-1008.
26. de Koning HP, Anderson LF, Stewart M, Burchmore RJ, Wallace LJ, Barrett MP: The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: Additional insights on diamidine resistance in African trypanosomes. Antimicrob Agents Chemother (2004) 48(5):1515-1519.
27. Liu B, Liu Y, Motyka SA, Agbo EE, Englund PT: Fellowship of the rings: The replication of kinetoplast DNA. Trends Parasitol (2005) 21(8):363-369.
28. Shlomai J: The structure and replication of kinetoplast DNA. Curr Mol Med (2004) 4(6):623-647.
29. Macadam RF, Williamson J: Drug effects on the fine structure of Trypanosoma rhodesiense: Diamidines. Trans R Soc Trop Med Hyg (1972) 66(6):897-904.
30. Docampo R, de Souza W, Miranda K, Rohloff P, Moreno S: Acidocalcisomes - conserved from bacteria to man. Nat Rev Microbiol (2005) 3(3):251-261.
31. Wilkes JM, Mulugeta W, Wells C, Peregrine AS: Modulation of mitochondrial electrical potential: A candidate mechanism for drug resistance in African trypanosomes. Biochem J (1997) 326(3):755-761.
32. Edwards KJ, Jenkins TC, Neidle S: Crystal structure of a pentamidine-oligonucleotide complex: Implications for DNA-binding properties. Biochemistry (1992) 31(31):7104-7109.
33. Mallena S, Lee MP, Bailly C, Neidle S, Kumar A, Boykin DW, Wilson WD: Thiophene-based diamidine forms a 'super' AT binding minor groove agent. J Am Chem Soc (2004) 126(42):13659-13669.
34. Donkor IO, Huang TL, Tao B, Rattendi D, Lane S, Vargas M, Goldberg B, Bacchi C: Trypanocidal activity of conformationally restricted pentamidine congeners. J Med Chem (2003) 46(6):1041-1048.
35. Schnaufer A, Domingo G, Stuart K: Natural and induced dyskinetoplastic trypanosomatids: How to live without mitochondrial DNA. Int J Parasitol (2002) 32(9):1071-1084.
36. Basselin M, Denise H, Coombs GH, Barrett MP: Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob Agents Chemother (2002) 46(12):3731-3738.
37. Basselin M, Lawrence F, Robert-Gero M: Pentamidine uptake in Leishmania donovani and Leishmania amazonensis promastigotes and axenic amastigotes. Biochem J (1996) 316(Pt 2):631-634.
38. Reguera R, Balana Fouce R, Cubria JC, Alvarez Bujidos ML, Ordonez D: Putrescine uptake inhibition by aromatic diamidines in Leishmania infantum promastigotes. Biochem Pharmacol (1994) 47(10):1859-1866.
39. Calonge M, Johnson R, Balana-Fouce R, Ordonez D: Effects of cationic diamidines on polyamine content and uptake on Leishmania infantum in in vitro cultures. Biochem Pharmacol (1996) 52(6):835-841.
40. Hasne MP, Ullman B: Identification and characterization of a polyamine permease from the protozoan parasite Leishmania major. J Biol Chem (2005) 280(15):15188-15194.
41. Bray PG, Barrett MP, Ward SA, de Koning HP: Pentamidine uptake and resistance in pathogenic protozoa: Past, present and future. Trends Parasitol (2003) 19(5):232-239.
42. Croft SL, Brazil RP: Effect of pentamidine isethionate on the ultrastructure and morphology of Leishmania mexicana amazonensis in vitro. Ann Trop Med Parasitol (1982) 76(1):37-43.
43. Hentzer B, Kobayasi T: The ultrastructural changes of Leishmania tropica after treatment with pentamidine. Ann Trop Med Parasitol (1977) 71(2):157-166.
44. 2+, pentamidine, and WR-6026 on mitochondrial membrane potential in situ. Biochem J (1992) 284(2):463-467.
45. Mehta A, Shaha C: Apoptotic death in Leishmania donovani promastigotes in response to respiratory chain inhibition: Complex II inhibition results in increased pentamidine cytotoxicity. J Biol Chem (2004) 279(12):11798-11813.
46. Mukherjee A, Padmanabhan PK, Sahani MH, Barrett MP, Madhubala R: Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani. Mol Biochem Parasitol (2006) 145(1):1-10.
47. Lanteri CA, Trumpower BL, Tidwell RR, Meshnick SR: DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae. Antimicrob Agents Chemother (2004) 48(10):3968-3974.
48. Basselin M, Robert-Gero M: Alterations in membrane fluidity, lipid metabolism, mitochondrial activity, and lipophosphoglycan expression in pentamidine-resistant Leishmania. Parasitol Res (1998) 84(1):78-83.
49. Basselin M, Badet-Denisot MA, Robert-Gero M: Modification of kinetoplast DNA minicircle composition in pentamidine-resistant Leishmania. Acta Trop (1998) 70(1):43-61.
50. Coelho AC, Beverley SM, Cotrim PC: Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major. Mol Biochem Parasitol (2003) 130(2):83-90.
51. de Souza EM, Lansiaux A, Bailly C, Wilson W, Hu Q, Boykin DW, Batista MM, Araujo-Jorge TC, Soeiro MN: Phenyl substitution of furamidine markedly potentiates its anti-parasitic activity against Trypanosoma cruzi and Leishmania amazonensis. Biochem Pharmacol (2004) 68(4):593-600.
52. Ridley R, Toure Y: Winning the drugs war. Nature (2004) 430(7002):942-943.
53. Fulton J: The course of Plasmodium relictum infection in canaries and the treatment of bird and monkey malaria with synthetic bases. Ann Trop Med Parasitol (1940) 34:53-66.
54. Das BP, Boykin DW: Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. J Med Chem (1977) 20(4):531-536.
55. Bell CA, Hall JE, Kyle OE, Grogl M, Ohemeng KA, Allen MA, Tidwell RR: Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis. Antimicrob Agents Chemother (1990) 34(7):1381-1386.
56. Stead AM, Bray PG, Edwards IG, de Koning HP, Elford BC, Stacks PA, Ward SA: Diamidine compounds: Selective uptake and targeting in Plasmodium falciparum. Mol Pharmacol (2001) 59(5):1298-1306.
57. Kirk K: Membrane transport in the malaria-infected erythrocyte. Physiol Rev (2001) 81(2):495-537.
58. Francis SE, Sullivan DJ Jr, Goldberg DE: Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu Rev Microbiol (1997) 51:97-123.
59. Biagini GA, Pasini EM, Hughes R, de Koning HP, Vial HJ, O'Neill PM, Ward SA, Bray PG: Characterization of the choline carrier of Plasmodium falciparum: A route for the selective delivery of novel antimalarial drugs. Blood (2004) 104(10):3372-3377.
60. Biagini GA, Ward SA, Bray PG: Malaria parasite transporters as a drug-delivery strategy. Trends Parasitol (2005) 21(7):299-301.
61. Ansede JH, Anbazhagan M, Brun R, Easterbrook JO, Hall JE, Boykin DW: O-alkoxyamidine prodrugs of furamidine: In vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection. J Med Chem (2004) 47(17):4335-4338.
62. Clement B, Raether W: Amidoximes of pentamidine: Synthesis, trypanocidal and leishmanicidal activity. Arzneimittelforschung (1985) 35(7):1009-1014.
63. Tidwell R, Boykin D: Dicationic DNA minor groove binders as antimicrobial agents. In: DNA and RNA Binders. Demeunynck M, Bailly C, Wilson WD (Eds), Wiley-VCH, Weinheim, Germany (2003) 2:414-460.
64. Clement B, Immel M, Terlinden R, Wingen FJ: Reduction of amidoxime derivatives to pentamidine in vivo. Arch Pharm (Weinheim) (1992) 325(1):61-62.
65. Steck EA, Kinnamon KE, Davidson DE Jr, Duxbury RE, Johnson AJ, Masters RE: Trypanosoma rhodesiense: Evaluation of the antitrypanosomal action of 2,5-bis(4-guanylphenyl)furan dihydrochloride. Exp Parasitol (1982) 53(1):133-144.
66. Boykin D, Kumar A, Bender B, Hall J, Tidwell R: Anti-pneumocystis activity of bis-amidoximes and bis-O-alkylamidoxime prodrugs. Bioorg Med Chem Lett (1996) 6:3017-3020.
67. Zhou L, Thakker DR, Voyksner RD, Anbazhagan M, Boykin DW, Hall JE, Tidwell RR: Metabolites of an orally active antimicrobial prodrug, 2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime, identified by liquid chromatography/tandem mass spectrometry. J Mass Spectrom (2004) 39(4):351-360.
68. Ismail MA, Brun R, Easterbrook JD, Tanious FA, Wilson WD, Boykin DW: Synthesis and antiprotozoal activity of aza-analogues of furamidine. J Med Chem (2003) 46(22):4761-4769.
69. Ansede JH, Voyksner RD, Ismail MA, Boykin DW, Tidwell RR, Hall JE: In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis. Xenobiotica (2005) 35(3):211-226.
70. Donkor IO, Assefa H, Rattendi D, Lane S, Vargas M, Goldberg B, Bacchi C: Trypanocidal activity of dicationic compounds related to pentamidine. Eur J Med Chem (2001) 36(6):531-538.
71. Mayence A, Vanden Eynde JJ, Krogstad FM, Krogstad DJ, Cushion MT, Huang TL: Parallel solution-phase synthesis of conformationally restricted congeners of pentamidine and evaluation of their antiplasmodial activities. J Med Chem (2004) 47(10):2700-2705.
72. Mayence A, Vanden Eynde JJ, Huang TL: Evidences for the formation of bisbenzamidine-heme complexes in cell-free systems. Bioorg Med Chem Lett (2004) 14(7):1625-1628.
73. Mayence A, Vanden Eynde JJ, LeCour L Jr, Walker LA, Tekwani BL, Huang TL: Piperazine-linked bisbenzamidines: A novel class of antileishmanial agents. Eur J Med Chem (2004) 39(6):547-553.
74. Brendle JL, Outlaw A, Kumar A, Boykin DW, Patrick DA, Tidwell RR, Werbovetz KA: Antileishmanial activities of several classes of aromatic dications. Antimicrob Agents Chemother (2002) 46(3):797-807.
75. Stephens CE, Brun R, Salem MM, Werbovetz KA, Tanious F, Wilson WD, Boykin DW: The activity of diguanidino and 'reversed' diamidino 2,5-diarylfurans versus Trypanosoma cruzi and Leishmania donovani. Bioorg Med Chem Lett (2003) 13(12):2065-2069.
76. Rowland EC, Moore-Lai D, Seed JR, Stephens CE, Boykin DW: Inhibition of in vitro intracellular growth of Trypanosoma cruzi by dicationic compounds. J Parasitol (2003) 89(5):1078-1080.
77. Arafa RK, Brun R, Wenzler T, Tanious FA, Wilson WD, Stephens CE, Boykin DW: Synthesis, DNA affinity, and antiprotozoal activity of fused ring dicationic compounds and their prodrugs. J Med Chem (2005) 48(17):5480-5488.
78. Ismail MA, Brun R, Wenzler T, Tanious FA, Wilson WD, Boykin DW: Dicationic biphenyl benzimidazole derivatives as antiprotozoal agents. Bioorg Med Chem (2004) 12(20):5405-5413.
79. Ismail MA, Batista-Parra A, Miao Y, Wilson WD, Wenzler T, Brun R, Boykin DW: Dicationic near-linear biphenyl benzimidazole derivatives as DNA-targeted antiprotozoal agents. Bioorg Med Chem (2005) 13(24):6718-6726.
80. Ismail MA, Brun R, Wenzler T, Tanious FA, Wilson WD, Boykin DW: Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydroimidazo[1,2-a]pyridines as antiprotozoal agents. J Med Chem (2004) 47(14):3658-3664.
81. Bhattacharya G, Gerena L, Jiang S, Werbovetz KA: Activity of amidine-containing diphenylureas against P falciparum. Lett Drug Des Discovery (2005) 2(2):162-164.
82. Ancelin ML, Calas M, Bonhoure A, Herbute S, Vial HJ: In vivo antimalarial activities of mono- and bis quaternary ammonium salts interfering with Plasmodium phospholipid metabolism. Antimicrob Agents Chemother (2003) 47(8):2598-2605.
83. Nicolas O, Margout D, Taudon N, Wein S, Calas M, Vial HJ, Bressolle FM: Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. Antimicrob Agents Chemother (2005) 49(9):3631-3639.
84. Kelly J, Winter R, Peyton D, Hinrichs D, Riscoe M: Optimization of xanthones for antimalarial activity: The 3,6-bis-ω-diethylaminoalkoxyxanthone series. Antimicrob Agents Chemother (2002) 46(1):144-150.
85. Kelly JX, Winter RW, Cornea A, Peyton DH, Hinrichs DJ, Riscoe M: The kinetics of uptake and accumulation of 3,6-bis-ω-diethylaminoamyloxyxanthone by the human malaria parasite Plasmodium falciparum. Mol Biochem Parasitol (2002) 123(1):47-54.
86. Salom-Roig XJ, Hamzé A, Calas M, Vial HJ: Dual molecules as new antimalarials. Comb Chem High Throughput Screen (2005) 8(1):49-62.
87. Yeramian P, Meshnick SR, Krudsood S, Chalermrut K, Silachamroon U, Tangpukdee N, Allen J, Brun R, Kwiek J, Tidwell R, Looareesuwan S: Efficacy of DB289 in Thai patients with Plasmodium vivax or acute, uncomplicated Plasmodium falciparum infections. J Infect Dis (2005) 192(2):319-322.